Issue 65

Psychedelic profiles: ibogaine

Ibogaine is a psychoactive compound found in several plants, most notably in the roots of the iboga tree, and has been used medicinally and ceremoniously in West Africa for centuries.

Although ibogaine is not listed as a scheduled substance by the United Nations, possession of it is strictly regulated or prohibited in several Western countries – restricting its adoption.

The entheogen has an established history in the treatment of substance use disorders, particularly in South America where its use remains unregulated. Ibogaine has the potential to decrease substance misuse, particularly opioid use disorder, which has become an epidemic across North America.

Brain imaging studies suggest high doses of psilocybin disrupt negative thought patterns through frenzied neurodynamics, which creates different neural pathways than those habitually used.

EXPLORE OUR PSYCHEDELIC SERIES

ELEUSIS GOES PUBLIC LEADING TO THE CREATION OF A US$450 MILLION COMPANY

The UK-based company merged with Silver Spike Acquisition Corp and will apply to list on the NASDAQ under the symbol ELEU.

Read More

THE FUTURE OF PSYCHEDELIC MEDICINES WILL BE DRUGS YOU'VE NEVER HEARD OF

Dr Goonatilake of University College London spoke with VICE on the rise of psychedelic research and artificial intelligence.

Read More

BUSINESS AND INVESTMENT

Numinus reports Q1 2022 financial results.

MAPS obtains MHRA innovation passport for MDMA therapy in the UK.

Mindcure: Despite market slump, ‘everything is moving in the right direction.’

Jupiter Wellness to manage MDMA development programmes.

What to expect in neuroscience, biotech and psychedelics in 2022.

FDA clears MindMed IND for treatment of anxiety disorder.

The Psychedelics as Medicine Report: Third Edition

The 200+ page Psychedelics as Medicine Report: Third Edition is the most comprehensive analysis of the psychedelic healthcare industry, empowering investors, operators and regulators to make informed decisions.

Key findings:

  • The medical psychedelic market is valued at US$190 million, and is expected to exceed US$2.4 billion by 2026.
  • Investment in psychedelic companies has now surpassed US$2 billion.
  • Two-thirds of North Americans and Europeans support the legalisation of psychedelic-assisted therapy.
Download your complimentary copy

SCIENCE AND RESEARCH

Blossom: Ketamine effective for alcoholism, not PTSD?

Debunking the myth of ‘Blue Mondays.’

UNITy awarded UCL grant for psychedelic research in Brazil.

DMT-assisted therapy: changing the way we think about depressive disorders.

Australian companies ramp up MDMA and psilocybin trials.

Ketamine an ‘intriguing new therapy’ for alcoholism.

REGULATION AND LEGISLATION

MDMA is finally being legalised for mental health therapy.

Virginia psilocybin decriminalisation bill enjoys bipartisan support.